SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:9951008.
  • 2
    George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994;331:12071211.
  • 3
    George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practical guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:340.
  • 4
    McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997;126:307314.
  • 5
    Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenia purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol 2002;81(6):312319.
  • 6
    Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002;118:933944.
  • 7
    Portielje JEA, Westendorp RGJ, Nelemans HCK, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:25492554.
  • 8
    Vianelli N, Valdre L, Fiacchini M, et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica 2001;86:504509.
  • 9
    Reff ME, Camer K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435445.
  • 10
    Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:21882195.
  • 11
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 1998;16:28252833.
  • 12
    Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Semin Oncol 2000;27:7985.
  • 13
    Perotta P, Sunnemberg JS, Ratanatharathorn V. Rituxan in the treatment of chronic idiopathic thrombocytopenia purpura (ITP). Blood 1999;94:49a.
  • 14
    Mow BM, Hook CC. Rituximab for the treatment of refractory immune thrombocytopenic purpura—case report. Blood 1999;94:3526a.
  • 15
    Bussell JB. Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. Semin Oncol 2000;27:9198.
  • 16
    Saleh MN, Gutheil J, Moore M, et al. A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura. Blood 2000;96:1086a.
  • 17
    Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27:99103.
  • 18
    Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952957.
  • 19
    Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol 2001;66:408.
  • 20
    Patel K, Berman J, Ferber A, Caro J. Refractory autoimmune thrombocytopenic purpura: treatment with Rituximab. Am J Hematol 2001;67:5960.
  • 21
    Grossi A, Santini V, Longo G, Balestri F, Ferrini PR. Treatment with anti-CD20 antibodies of patients with autoimmune thrombocytopenia with or without haemolytic anaemia: worsening of the hemoglobin level. Blood 2001;96:1089a.
  • 22
    Rosenthal E, Karsenti JM, Pesce A, Cassutto JP. Anti-CD20 monoclonal antibody (Rituximab) administration in patients with refractory immunologic thrombocytopenic purpura. Blood 2001;98:2194a.
  • 23
    Schuler US, Florek M, Mueller J, Haack A, Weise M, Lehmann HU, Ehninger G. Successful rituximab treatment of immune thrombocytopenia (ITP) in an elderly lady with mastocytosis. Blood 2001;98:3875a.
  • 24
    Cooper N, Bussel J. Rituxan treatment in patients with immune thrombocytopenic purpura (ITP). Blood 2001;98:2180a.
  • 25
    Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99:38723873.
  • 26
    Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune haemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87:189195.
  • 27
    Aggarwal A, Catlett JP. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura. South Med J 2002;95(10):12091212.
  • 28
    Giagounidis AAN, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95100.
  • 29
    Cohen Y, Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab. Hematol J 2002;3:6162.
  • 30
    Heelan BT, Tormey V, Amlot P, Payne E, Metha A, Webster ADB. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome. Br J Haematol 2002;118:10781081.
  • 31
    Delgado J, Bustos JG, Jimenez-Yuste V, Hernandez-Navarro F. Anti-CD20 monoclonal antibody in refractory immune thrombocytopenic purpura. Hematologica 2002;87:215216.
  • 32
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232239.
  • 33
    D'Arena G, Luigiavigliotti M, Iodice G, Tartarone A, Matera R, Di Renzo N. Late and long- lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximab. Leuk Lymphoma 2003;44(3):561562.
  • 34
    Zaja F, Vianelli N, Sperotto A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003;88:538546.
  • 35
    Introna M, Golay J, Barbui T. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura? Haematologica 2003;88(5):482484.
  • 36
    Riksen NP, Keuning JJ, Vreugdenhil G. Rituximab in the treatment of relapsing idiopathic thrombocytopenic purpura. Neth J Med 2003;61(7):262265.
  • 37
    Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune haemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78(11):13401346.
  • 38
    Narang M, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane CD20 (rituximab). Am J Hematol 2003;74:263267.
  • 39
    Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998;92:34903491.
  • 40
    Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;12:10851086.
  • 41
    Morselli M, Luppi M, Potenza L, et al. Mixed warm and cold autoimmune haemolytic anemia: complete recovery after 2 courses of rituximab treatment. Blood 2002;99:34783479.
  • 42
    Ahrens N, Kingreen D, Seltsam A, Salama A. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 2001;114:244245.
  • 43
    Berentsen S, Tjonnfjord GE, Brudevold R, et al. Favorable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001;115:7983.
  • 44
    McMahon C, Babu L, Hodgson A, Hayat A, Connell NO, Smith OP. Childhood refractory autoimmune haemolytic anaemia: is there a role for anti-CD20 therapy (rituximab)? Br J Haematol 2002; 117:480483.
  • 45
    Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:15111513.
  • 46
    Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922924.
  • 47
    Engelhardt M, Jacob A, Rüter B, Trepel M, Hirsch F, Lübbert M. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood 2002;100:19221923.
  • 48
    Ahrens N, Heymann G, Meyer O, Kiesewetter H, Salama A. Results of treatment with Rituximab (Anti-CD20) in three patients with autoimmune haemolytic anemia and/or immune thrombocytopenia and a concise review of reported cases. Infusionsther Transfusionsmed 2002;29:277281.
  • 49
    Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and haemolytic anemia. Blood 2001;97:39953997.
  • 50
    Zaja F, Ve Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002;46:22522264.
  • 51
    Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100:34263428.
  • 52
    Specks U, Frevenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:28362840.
  • 53
    Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923924.
  • 54
    Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukaemia: further regulation by CD55 and CD59. Blood 2001;98:33833389.
  • 55
    Golay J, Gramigna R, Fachinetti V, Capello D, Gaidano G, Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 2002;119:923929.
  • 56
    Introna M, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. Blood 2002;100(Suppl 1):161a (abstract).
  • 57
    Hedge UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine associated immune thrombocytopenia in chronic lymphocytic leukaemia. Blood 2002;100:22602262.
  • 58
    Chan OC, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998;160:5159.
  • 59
    Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T-cell activation in rheumatoid synovium is B-cell dependent. J Immunol 2001;167:47104718.